NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has received CE marking in Europe for its Tumor BRACAnalysis CDx test. 

The test identifies tumors with mutations in the BRCA1 and BRCA2 genes. Myriad said that Tumor BRACAnalysis CDx is the only CE-marked tumor-based companion diagnostic test. It identifies patients who may benefit from AstraZeneca's Lynparza (olaparib), a poly ADP-ribose polymerase inhibitor. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.